Shawn A. Scranton

Dura Pharmaceuticals, Inc. markets and sells prescription products that treat infectious and respiratory diseases. Dura focuses on products and transactions that leverage its sales and marketing organization. Dura also intends, through the use of collaborative relationships, to develop the Spiros® motorized blisterdisk and Spiros® S2 pulmonary drug delivery systems for the local and systemic delivery of a wide range of medications. It is located in San Diego, CA.

Kalypsys, Inc. discovered and developed novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases. The firm advanced its proprietary lead program, a novel, non-corticosteroid small molecule formulated for intranasal delivery, into clinical proof of concept studies. The company was founded by Pratik Shah, Jeremy S. Caldwell, Randall W. King, Kevin D. Lustig, Peter G. Schultz and Robert Downs in 2001 and was headquartered in Solana Beach, CA.

Salmedix, Inc. develops oncology and small molecule drugs to treat hematological malignancies. The company's product, Treanda, is currently in Phase II clinical trials in the United States and Canada for the treatment of indolent (slowly progressing) non-Hodgkin's lymphoma. It was founded in 2000 and is located in San Diego, CA.

Victory Pharma, Inc. was a specialty pharmaceutical company that acquired markets and developed prescription pharmaceutical products that treat pain and related conditions. It marketed these products to health care professionals through its experienced U.S. commercial organization. The company was founded in 2003 and was headquartered in San Diego, CA.

Pfenex, Inc. is a development and licensing Biotechnology Company, which focuses on leveraging its Pfenex Expression Technology platform for developing and improving protein therapies. Its products include PF708, PF743, PF745, CRM197, PF810, PF753 and PFXX. The company was founded on November 19, 2009 and is headquartered in San Diego, CA.

Sentynl Therapeutics, Inc. acquires, develops and commercializes prescription products. The company was founded by Matthew Heck and is headquartered in Solana Beach, CA.

Amber Ophthalmics is a clinical-stage biotechnology company that focuses on ophthalmology. The company is based in San Diego, CA. The company has developed a patent-protected, first-in-class unmodified antisense oligonucleotide that inhibits a cell membrane hemichannel forming protein called connexin43 (cx43).